Vertex Pharmaceuticals' unchanged guidance and disappointing trial outcomes for its investigative pain relief treatment led ...

We recently published 10 Big Names Bleed Double Digits. Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) is one of the ...

Vertex Pharmaceuticals’ second quarter 2025 results exceeded Wall Street’s expectations, but the market responded sharply ...

Vertex Pharmaceuticals ( VRTX) plunged after Q2 earnings and is now down 21% over the past year. The company has historically ...

Vertex Pharmaceuticals Incorporated's stock drop is overblown. With strong CF revenue, pipeline potential, & insider ...

Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $200.0 and $460.0 for Vertex Pharmaceuticals, spanning the last ...

Vertex Pharmaceuticals' Seaport headquarters buildings have been refinanced for $1 billion, putting a ten-figure value on an ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $481.56, ...

Fintel reports that on August 6, 2025, Wells Fargo upgraded their outlook for Vertex Pharmaceuticals (NasdaqGS:VRTX) from ...